Cellares' partnership announcements and SEC filings.

Bristol Myers, Cellares Ink $380M Deal to Boost CAR-T Therapy Production

Apr 22, 2024, 01:01 PM

Bristol Myers Squibb has signed a significant $380 million agreement with Cellares to enhance the production and supply of CAR-T cell therapies. This partnership aims to extend the reach of these therapies to more patients across the United States, European Union, and Japan. The deal involves Cellares acting as a contract manufacturer to help meet the growing demand for these innovative treatments.